OncoNext™ Risk – Melanoma
OncoNext™ Risk Melanoma is a diagnostic test, developed by GENOMA Group, which allows you to perform a multiple genetic analysis to assess the predisposition to the development of Melanoma. The test, therefore, allows you to identify patients at risk of developing this neoplasia by analyzing their DNA.
OncoNext™ Risk – Pancreas
OncoNext™ Risk – Oncoscreening Complete
OncoNext ™ Risk OncoScreening Complete is a diagnostic test, developed by GENOMA Group, which allows you to perform a multiple genetic analysis to assess the predisposition to hereditary cancers, including: Breast Cancer, Ovarian / Uterus Cancer, Colorectal Cancer, Stomach Cancer, Pancreatic Cancer, Prostate Cancer, Skin Cancer (Melanoma), Brain Cancer, Kidney Cancer and Pheochromocytoma / Paraganglioma. […]
OncoNext™ Liquid Monitor – Lung: Analysis of circulating tumor DNA (ctDNA)
Eurofins Genoma Group’s OncoNext ™ Liquid genetic tests were designed to study somatic mutations of circulating tumor DNA (ctDNA) in peripheral blood in patients with cancer or at high risk of cancer. The study of ctDNA, also called liquid biopsy, is the most innovative tool that the oncologist can use today. Thanks the OncoNext ™ […]
OncoNext™ Liquid Monitor – Breast: Analysis of circulating tumor DNA (ctDNA)
Eurofins Genoma Group’s OncoNext ™ Liquid genetic tests were designed to study somatic mutations of circulating tumor DNA (ctDNA) in peripheral blood in patients with cancer or at high risk of cancer. The study of ctDNA, also called liquid biopsy, is the most innovative tool that the oncologist can use today. Thanks the OncoNext ™ Liquid test the clinician […]
